Title
Image-guided combination chemotherapy and photodynamic therapy using a mitochondria-targeted molecular probe with aggregation-induced emission characteristics.

Permalink
https://escholarship.org/uc/item/6130b2ttb

Journal
Chemical science, 6(8)

ISSN
2041-6520

Authors
Zhang, Chong-Jing
Hu, Qinglian
Feng, Guangxue
et al.

Publication Date
2015-08-01

DOI
10.1039/c5sc00826c

Peer reviewed
Image-guided combination chemotherapy and photodynamic therapy using a mitochondria-targeted molecular probe with aggregation-induced emission characteristics†

Chong-Jing Zhang,†a Qinglian Hu,†a Guangxue Feng, a Ruoyu Zhang, a Youyong Yuan, a Xianmao Lu a and Bin Liu*ab

Subcellular targeted cancer therapy and in situ monitoring of therapeutic effect are highly desirable for clinical applications. Herein, we report a series of probes by conjugating zero (TPECM-2Br), one (TPECM-1TPP) and two (TPECM-2TPP) triphenylphosphine (TPP) ligands to a fluorogen with aggregation-induced emission (AIE) characteristics. The probes are almost non-emissive as molecularly dissolved species, but they can light up in cell cytoplasm or mitochondria. TPECM-2TPP is found to be able to target mitochondria, depolarize mitochondria membrane potential and selectively exert potent chemo-cytotoxicity on cancer cells. Furthermore, it can efficiently generate singlet oxygen with strong photo-toxicity upon light illumination, which further enhances its anti-cancer effect. On the other hand, TPECM-1TPP can also target mitochondria and generate singlet oxygen to trigger cancer cell apoptosis, but it shows low cytotoxicity in dark. Meanwhile, TPECM-1 TPP can report the cellular oxidative stress by visualizing the morphological changes of mitochondria. However, TPECM-2Br does not target mitochondria and shows no obvious anticancer effect either in dark or under light illumination. This study thus highlights the importance of molecular probe design, which yields a new generation of subcellular targeted molecular theranostic agents with multi-function, such as cancer cell imaging, chemotherapy, photodynamic therapy, and in situ monitoring of the therapeutic effect in one go.

Introduction

Despite significant advances in cancer diagnosis and chemotherapy, cancer patients continue to suffer from drug resistance, frequent relapses and severe side effects.1,2 This highlights the need to develop anticancer agents with new mechanisms of action. Photodynamic therapy (PDT) as a safe, minimally invasive treatment is driven by activating photosensitizers (PSs) to generate reactive oxygen species (ROS), prevalently singlet oxygen for effective cancer cell killing.3–5 The combination of PDT and chemotherapy with different therapeutic mechanisms has been proved effective in improving the therapeutic efficiency with minimized side effects, which was achieved mainly via two approaches.6 The first is to sequentially administrate anticancer drug and PS.7 The other is to simultaneously administrate an anticancer drug and a PS which are conjugated together8–10 or simply co-encapsulated in nanocarriers.11,12 Previous studies have also revealed that the therapeutic efficiency could be further improved when subcellular targeted delivery of therapeutic reagents was achieved as not all the organelles in the cancer cells are equally sensitive to the treatment.13 In addition, due to the extremely short half-life (<40 ns) and small radius of action (<20 nm) of singlet oxygen in biological systems,14,15 it is expected that direct delivering of PS to specific cells as well as to hypersensitive subcellular sites would greatly enhance the PDT efficiency.

Mitochondria are vital sub-cellular organelles to eukaryotic cells, which play valuable roles in energy production, ROS generation and cellular signaling.13,16 Cancer cells often exhibit various degrees of abnormal mitochondrial functions such as change in energy metabolism, higher mitochondrial membrane potential and increased oxidative stress, which provide opportunities to target cancer cell mitochondria for optimal therapeutic efficiency.17,18 Several mitochondrial-targeted compounds have been developed as potential anti-cancer agents which either directly influence mitochondria or functionally incur the metabolic alterations in cancer cells with mitochondrial dysfunction.19–22 A number of evidences also
indicate that the damage of mitochondria is the main reason for PDT-induced cell apoptosis. Therefore, mitochondrion is the ideal organelle for combined chemotherapy and PDT. To realize mitochondria targeted therapy, the popular strategy is to conjugate mitochondria targeting moiety (e.g. mitochondrial localization peptide and lipophilic cation group) to drug/PSs or nanocarriers loaded with therapeutic reagents. It has been reported that lipophilic triphenylphosphonium can help to render several thousand-folds accumulation of its conjugates in mitochondria. However, as most of the PSs are hydrophobic, they would naturally aggregate in the limited mitochondrial space. The aggregation of PSs will impose a quenched fluorescence emission as well as reduced singlet oxygen generation, which will compromise the quality of imaging and the effect of PDT.

Recently, there is an increasing interest in the development of fluorogens with aggregation induced emission (AIE) characteristics for biological sensing, imaging and cancer therapy applications. The AIE fluorogens (AIEgens) generally have rotor structures, which show very weak fluorescence in molecularly dissolved state but become highly emissive upon aggregation formation. The optical properties of AIEgens are different from traditional fluorophores, which enabled them to be developed into light-up probes and bright fluorescent nanoparticles for the detection of molecular targets and continuous monitoring of biological processes. In addition, several AIEgens were found to show effective ROS generation capabilities for efficient cell ablation. We recently also discovered that properly designed AIEgens could also serve as potential potent chemo-drugs for cancer cell killing due to their preferential accumulation in cancer cell mitochondria. The versatile functions and exciting properties of AIEgens offer the unique opportunity to further develop multifunctional molecular probes for image-guided therapy.

To explore simple molecular probe based image-guided combination chemotherapy and PDT, in this contribution, we developed a series of probes based on a new AIE PS (TPECM-2Br). Lipophilic triphenylphosphonium as a mitochondria targeting moiety was selected to conjugate to TPECM-2Br because it possesses a delocalized positive charge and can selectively accumulate in cancer cell mitochondria by trans-membrane potential gradient. The obtained TPECM-1TPP and TPECM-2TPP are almost non-emissive in aqueous media, but they emit strong red fluorescence in aggregated state. The probes showed preferential cellular uptake by cancer cells relative to normal cells, and they can be specifically localized in mitochondria to turn on their fluorescence. TPECM-2TPP is found to be able to depolarize mitochondria membrane potential and selectively exert potent chemo-cytotoxicity on the studied cancer cells. Furthermore, the probe can efficiently generate reactive singlet oxygen with strong photo-toxicity upon light illumination, which further enhances the anti-cancer effect. Interestingly, TPECM-1TPP only shows high cytotoxicity upon light illumination and has the ability to generate singlet oxygen to cause mitochondrial oxidative stress and trigger cell death. However, TPECM-2Br exhibits low cytotoxicity both in dark and upon light illumination in the studied cell lines. These results highlight that molecular design plays an important role in cancer cell treatment.

**Results and discussion**

The probes of TPECM-2Br, TPECM-1TPP and TPECM-2TPP were synthesized according to Scheme 1. Briefly, two different benzophenone derivatives were reacted in the presence of Zn and TiCl4 to give 1 in 27.2% yield, which was subsequently treated with n-BuLi and DMP to give 2 in 59.7% yield. 2 was first reacted with the Grignard reagent and the resulted secondary alcohol was further oxidized to generate 3 in 61.5% yield. 3 was subsequently treated with boron tribromide, followed by reaction with 4-dibromobutane to give 4 in 13.5% yield. The mixture of 4, ammonium acetate and malononitrile adsorbed on silica gel was heated at 100 °C for 40 minutes to give TPECM-2Br in 74.0% yield, which was then reacted with triphenylphosphine to generate TPECM-1TPP in 13.8% yield and TPECM-2TPP in 18.2% yield. The purified intermediates and products were well characterized by NMR and mass spectroscopies which confirmed their right structures with high purity (ESI Fig. 1–4†).

We first investigated the photophysical properties of TPECM-2Br. TPECM-2Br has an absorption maximum at 410 nm in DMSO–water (v/v = 1 : 199) (ESI Fig. 5A†). The photoluminescence (PL) spectra of TPECM-2Br were studied in DMSO–water mixtures with different water fractions (fwater). As shown in Fig. 1A, TPECM-2Br is faintly fluorescent in DMSO as the compound is well dissolved as molecular species, and the free molecular motion consumes energy, which favors non-radiative decay. However, with gradual increasing fwater, TPECM-2Br becomes highly emissive with an emission maximum at 628 nm, showing a characteristic AIE phenomenon. This is due to formation of nanoparticles which activate the radiative decay channel to turn-on the fluorescence. TPECM-1TPP and TPECM-2TPP in DMSO–water (v/v = 1 : 199) showed similar absorption profiles to that of TPECM-2Br. However, their emission spectra in water are very different. As shown in Fig.1B, TPECM-2Br is

![Scheme 1](image-url)
highly emissive in water, while TPECM-1TPP shows weak fluorescence and TPECM-2TPP is almost non-emissive. To test the AIE characteristics of TPECM-1TPP and TPECM-2TPP, the mixtures of hexane and isopropyl alcohol were applied to study their fluorescent signals. As shown in Fig. 1C and D, TPECM-1TPP and TPECM-2TPP become highly emissive when the volume fraction of hexane is gradually increased to more than 80% and the nano-aggregates formation was also confirmed by laser light scattering (LLS) [ESI Fig. 5B–C†]. These results indicate that all the three probes are AIE active.

To assess the intracellular distribution profiles of the probes, HeLa cells were firstly selected due to their well-defined mitochondrial network. As shown in Fig. 2, TPECM-1TPP and TPECM-2TPP display a characteristic mitochondrial localization pattern, which is consistent with that of the Mito-tracker green, confirming that TPP can effectively drive the accumulation of both probes into mitochondria [Fig. 2A–D and F–I]. On the other hand, TPECM-2Br is randomly dispersed in the cytoplasm which does not co-localize well with Mito-tracker green (Fig. 2K–N). The Pearson’s correlation coefficients are used to quantify the overlaps between the probes and Mito-tracker green, which are 0.96, 0.96 and 0.50 for TPECM-1TPP, TPECM-2PP and TPECM-2Br, respectively (Fig. 2E, J and O).

The effect of probe concentration on the cellular uptake of TPECM-1TPP and TPECM-2TPP in HeLa cells was also studied. From the confocal images, it is obvious that the higher probe concentration leads to brighter red fluorescence in HeLa cells for both probes [ESI Fig. 6 and 7†]. Quantitative analysis of the fluorescence intensity shows that the cellular uptake of TPECM-1TPP is ~25% less efficient than that for TPECM-2TPP in HeLa cells under the same probe concentration, which indicates that TPP favors both mitochondria targeting and cellular uptake (ESI Fig. 8†). We then monitored the cellular uptake of 2 μM TPECM-1TPP in HeLa, MDA-MB-231 and NIH-3T3 cells at different time points. It was found that for each cell line, the image intensity increases with the probe incubation time from 1 h to 3 h. Quantitative analysis of the fluorescence intensity for the images obtained for cells upon 3 h incubation with the probes reveals that the uptake performance of TPECM-1TPP in HeLa and MDA-MB-231 cells is quite similar (ESI Fig. 6 and 9†), which is ~72% higher than that for NIH-3T3 cells calculated from the results of flow cytometry (ESI Fig. 10–11†). Similarly, TPECM-2TPP is also preferably accumulated in the tested cancer cells judging from confocal and flow cytometry studies (ESI Fig. 12–13†). The more accumulation of the probes in the tested cancer cells could be due to the higher mitochondrial membrane potential of cancer cells than that of normal cells. This potential deriviation has been reported to be approximately 60 mV which is sufficient to incur 10-fold greater accumulation of positively charged compounds in cancer cells according to the Nernst equation. 46

After confirming that both TPECM-1TPP and TPECM-2TPP are indeed located in mitochondria, we then tested whether the specific targeting could affect cell viability. MTT assays were used to study cytotoxicity of TPECM-2Br, TPECM-1TPP and TPECM-2TPP under dark. After 24 h incubation, TPECM-2Br and TPECM-1TPP exhibited low cytotoxicity even at a high concentration of 10 μM as more than 80% of the tested cells survived (Fig. 3A). On the contrary, TPECM-2TPP demonstrated much higher dark cytotoxicity with an IC_{50} value of 6.31 μM for HeLa cells. Similar results were also observed for MDA-MA-231 cancer cells, where TPECM-2Br and TPECM-1TPP exhibited no obvious cytotoxicity but TPECM-2TPP showed high dark cytotoxicity with an IC_{50} value of 4.03 μM (ESI Fig. 14 and 15†).

To understand the high dark toxicity for TPECM-2TPP, we studied the effect of the probe accumulation in mitochondria on its membrane potential using tetramethylrhodamine ethyl...
potent cytotoxicity. In addition, strong red absorption of ABDA decreases quickly, indicating that both TMRE could be detected when singlet oxygen attack the indicator, whose absorbance decreases upon interaction with singlet oxygen. As shown in Fig. 4, TPECM-2Br has no obvious toxicity even at a high concentration of 10 μM. However, TPECM-1TPP exhibits time- and power-dependent photocytotoxicity, which can kill more than 70% of HeLa cells at 5 μM, with an IC50 value of 3.13 μM upon white light illumination. The difference in photo-toxicity is largely because mitochondria are more prone to singlet oxygen attack than cytoplasm. In addition, TPECM-1TPP does not affect viability of NIH-3T3 cells as over 90% of cells survived after the treatment (Fig. 4D). As a consequence, TPECM-1TPP could serve as a good PS because of its low dark cytotoxicity, high photo-toxicity and selective targeting ability towards the tested cancer cells.

Additionally, TPECM-1TPP was also found to be able to visualize the mitochondria morphological changes under high oxidative stress induced by light-irradiation (ESI Fig 18†). As shown in Fig. 5, under the dark condition, mitochondria in TPECM-1TPP-treated cells were tubular-like. But after white light irradiation, mitochondria adopted small round shapes. The swelling of mitochondria is another evidence to indicate the depolarization of the mitochondrial membrane potential. As such, TPECM-1TPP is not only a good PS, but also an imaging tool to monitor the mitochondria morphological change during PDT.

For TPECM-2TPP, in addition to the high cytotoxicity under dark conditions, under light illumination, it could also generate singlet oxygen to bleach the indicator of ABDA. As shown in Fig. 6A, it took 20 μM TPECM-2TPP less than 6 min to almost completely bleach 100 μM ABDA under light irradiation. When the probe was used for cell based assays, the viabilities were studied for HeLa cells upon treatment with the probe under different durations of white light irradiation at a constant power density of 0.25 W cm−2, as shown in Fig. 6B. It can be observed that, as the irradiation time increases, the viabilities of cells decrease with time. However, under the irradiation of 0.25 W cm−2, over 50% of HeLa cells could survive after 2 h, which is significantly higher than other work using TPECM-2TPP as a PS. The reason is that the generation of singlet oxygen under light illumination is a time- and power-dependent process. As such, TPECM-1TPP is not recommended for PDT usage.
of 0.10 W cm$^{-2}$ (Fig. 6B) or under white light irradiation at different powers for a fixed period of time (Fig. 6C). At the same concentration of the probe, TPECM-2TPP showed stronger inhibition of cell viability with longer irradiation time at higher irradiation power. The high cytotoxicity and the singlet oxygen generation capability thus offered a new opportunity for TPECM-2TPP to be used as a unique molecular probe for combined chemotherapy and PDT. Notably, under white light illumination, the IC$_{50}$ value of the probe towards HeLa cells is 0.69 μM (ESI Fig. 15†), which is 8-fold lower than that of the probe without light irradiation (6.31 μM). The light-induced increase in cell killing efficiency of the probe was also observed in another cancer cell line (MDA-MB-231) where the probe showed an IC$_{50}$ value of 2.48 μM under light illumination which compares favorably to that obtained in the dark (4.03 μM). It is also important to note that TPECM-2TPP shows much less phototoxicity to NIH-3T3 than that for HeLa cells (Fig. 6D), which is consistent with the observation that NIH-3T3 cells uptake less amount of the probe than HeLa cells.

The MTT results were further confirmed by propidium iodide (PI) staining. PI, a cell impermeable dye, only stains dead cells or late apoptotic cells with damaged membrane. As shown in Fig. 7, only part of TPECM-2TPP-treated cells incubated under dark was stained whereas nearly all the cells were stained after they were exposed to white light irradiation (8 min, 0.10 W cm$^{-2}$). Meanwhile, when the cells were treated with both the probe and singlet oxygen scavenger (Vitamin C), much fewer cells were stained even after white light irradiation, indicating that the singlet oxygen generation plays an important role in cell killing. Collectively, these results indicate that the combination chemo-therapy and PDT provides higher anticancer effect compared to the single therapeutic approach alone.
Conclusion

In summary, we have systematically designed and synthesized three molecular probes with aggregation-induced emission characteristics. Without the targeting group, TPECM-2Br is randomly dispersed in cytoplasm and renders no obvious cytotoxicity in dark or under white light irradiation. By virtue of the subcellular targeting TPP group, both TPECM-1TPP and TPECM-2TPP are able to specifically aggregate and light up in mitochondria. With one TPP group, TPECM-1TPP shows low cytotoxicity to all the tested cells even at a concentration of 10 μM. However, it shows much higher cytotoxicity (IC_{50} = 3.13 μM) under light irradiation. In addition, TPECM-1TPP is able to monitor the morphological change of mitochondria, and its phototoxicity is more potent for HeLa and MDA-MB-231 cells than NIH-3T3 cells. The low dark cytotoxicity, high photo-cytotoxicity and preferable accumulation in the tested cancer cells than NIH-3T3 cells. The distinct performance among the three probes highlights the importance of molecular probe design in real-time image-guided combination therapy. In addition, as a good AIE PS, DiTPECM-1TPP and DiTPECM-2Br are able to specifically aggregate and light up in white light irradiation to yield an overall IC_{50} of 0.69 μM for HeLa cells. The distinct performance among the three probes represents the first molecular probe for image-guided combination chemotherapy and PDT without direct drug conjugation. The probe of TPECM-2TPP thus represents a new generation of subcellular targeted theranostic agent with multifunction, such as cancer cell detection, imaging, chemotherapy, and photodynamic therapy. The concept and simplicity in our probe design thus provides the basis for future design of molecule probes for targeted and image-guided combination therapy.

Acknowledgements

We thank the SMART (R279-000-378-592), the Ministry of Education (R279-000-391-112), Singapore NRF Investigatorship (R279-000-444-281) and the Institute of Materials Research and Engineering of Singapore (IMRE/14-8P1110) for financial support.

References

1 A. Umar, B. K. Dunn and P. Greenwald, Nat. Rev. Cancer, 2012, 12, 835–848.
2 L. Kelland, Nat. Rev. Cancer, 2007, 7, 573–584.
3 E. Secret, M. Maynadier, A. Gallud, M. Gary-Bobo, A. Chaix, E. Belamie, P. Maillard, M. J. Sailor, M. Garcia, J.-O. Durand and F. Cunin, Chem. Commun., 2013, 49, 4202–4204.
4 J. P. Celli, B. O. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma, B. W. Pogue and T. Hasan, Chem. Rev., 2010, 110, 2795–2838.
5 P. Agostinis and K. Berg, Ca-Cancer J. Clin., 2011, 61, 250–281.
6 M. Olivo, R. Bhuvaneswari, S. S. Lucky, N. Dendukuri and P. Soo-Ping Thong, Pharmaceuticals, 2010, 3, 1507–1529.
7 M.-F. Zuluaga and N. Lange, Curr. Med. Chem., 2008, 15, 1655–1673.
8 J. T. F. Lau, P.-C. Lo, W.-P. Fong and D. K. P. Ng, J. Med. Chem., 2012, 55, 5446–5454.
9 C. Lottner, R. Knuechel, G. Bernhardt and H. Brunner, Cancer Lett., 2004, 203, 171–180.
10 J. Králová, Z. Kejík, T. Bríza, P. Poucková, A. Král, P. Martásek and V. Král, J. Med. Chem., 2010, 53, 128–138.
11 A. Khdair, D. Chen, Y. Patil, L. Ma, Q. P. Dou, M. P. V. Shekhar and J. Panyam, J. Controlled Release, 2010, 141, 137–144.
12 A. Khdair, H. Handa, G. Mao and J. Panyam, Eur. J. Pharm. Biopharm., 2009, 71, 214–222.
13 L. Rajendran, H.-J. Knöllker and K. Simons, Nat. Rev. Drug Discovery, 2010, 9, 29–42.
14 A. Juarranz, P. Jaén, F. Sanz-Rodriguez, J. Cuevas and S. González, Clin. Transl. Oncol., 2008, 10, 148–154.
15 P. R. Ogilby, Chem. Soc. Rev., 2010, 39, 3181–3209.
16 X. Wang, S. Peralta and C. T. Moraes, Mitochondrial alterations during carcinogenesis: a review of metabolic transformation and targets for anticancer treatments, Elsevier Inc., 1st edn, vol. 119, 2013.
17 L. Galluzzi, N. Larochette, N. Zamzami and G. Kroemer, Oncogene, 2006, 25, 4812–4830.
18 H. K. Byoung, J. Plescia, Y. S. Ho, M. Meli, G. Colombo, K. Beebe, B. Scroggins, L. Neckers and D. C. Altieri, J. Clin. Invest., 2009, 119, 454–464.
19 R. A. J. Smith, R. C. Hartley and M. P. Murphy, Antioxid. Redox Signaling, 2011, 15, 3021–3038.
20 F. Wang, M. A. Ogasawara and P. Huang, Mol. Aspects Med., 2010, 31, 75–92.
21 S. R. Jean, D. V. Tulumello, S. P. Wisnovsky, E. K. Lei, M. P. Pereira and S. O. Kelley, ACS Chem. Biol., 2014, 9, 323–333.
22 L. Fulda, L. Galluzzi and G. Kroemer, Nat. Rev. Drug Discovery, 2010, 9, 447–464.
23 R. Hilf, J. Bioenerg. Biomembr., 2007, 39, 85–89.
24 N. M. Sakhrai and H. Padh, Drug Des., Dev. Ther., 2013, 7, 585–599.
25 S. P.-Y. Li, C. T.-S. Lau, M.-W. Louie, Y.-W. Lam, S. H. Cheng and K. K.-W. Lo, Biomaterials, 2013, 34, 7519–7532.
26 P. Prasad, I. Khan, P. Kondaiah and A. R. Chakravarty, Chem.–Europ., 2013, 19, 17445–17455.
27 J. Xu, F. Zeng, H. Wu, C. Hu and S. Wu, Biomacromolecules, 2014, 15, 4249–4259.
28 P. Rajaputra, G. Nkempang, R. Watley and Y. You, Bioorg. Med. Chem., 2013, 21, 379–387.
29 H. Shi, R. T. K. Kwok, J. Liu, B. Xing, B. Z. Tang and B. Liu, J. Am. Chem. Soc., 2012, 134, 17972–17981.
30 S. Samanta, S. Goswami, M. N. Hoque, A. Ramesh and G. Das, Chem. Commun., 2014, 50, 11833–11836.
31 X. Li, K. Ma, S. Zhu, S. Yao, Z. Liu, B. Xu, B. Yang and W. Tian, Anal. Chem., 2014, 86, 298–303.
32 Y. Li, H. Yu, Y. Qian, J. Hu and S. Liu, Adv. Mater., 2014, 26, 6734–6741.
33 E. Zhao, H. Deng, S. Chen, Y. Hong, C. W. T. Leung, J. W. Y. Lam and B. Z. Tang, Chem. Commun., 2014, 50, 14451–14454.
34 F. Hu, Y. Huang, G. Zhang, R. Zhao, H. Yang and D. Zhang, Anal. Chem., 2014, 86, 7987–7995.
35 Y. Yuan, R. T. K. Kwok, B. Z. Tang and B. Liu, J. Am. Chem. Soc., 2014, 136, 2546–2554.
36 R. T. K. Kwok, C. W. T. Leung, J. W. Y. Lam and B. Z. Tang, Chem. Soc. Rev., 2015, DOI: 10.1039/c4cs00325j.
37 J. Mei, Y. Hong, J. W. Y. Lam, A. Qin, Y. Tang and B. Z. Tang, Adv. Mater., 2014, 26, 5429–5479.
38 D. Ding, K. Li, B. Liu and B. Z. Tang, Acc. Chem. Res., 2013, 46, 2441–2453.
39 L. Zhang, N. He and C. Lu, Anal. Chem., 2015, 87, 1351–1357.
40 J. Liang, B. Z. Tang and B. Liu, Chem. Soc. Rev., 2015, 44, 2798–2811.
41 K. Li and B. Liu, Chem. Soc. Rev., 2014, 43, 6570–6597.
42 Y. Yuan, C.-J. Zhang, M. Gao, R. Zhang, B. Z. Tang and B. Liu, Angew. Chem., Int. Ed., 2015, 54, 1780–1786.
43 Y. Yuan, G. Feng, W. Qin, B. Z. Tang and B. Liu, Chem. Commun., 2014, 50, 8757–8760.
44 Q. Hu, M. Gao, G. Feng and B. Liu, Angew. Chem., Int. Ed., 2014, 53, 14225–14229.
45 J. S. Modica-Napolitano and J. R. Aprille, Adv. Drug Delivery Rev., 2001, 49, 63–70.
46 J. S. Modica-Napolitano and J. R. Aprille, Cancer Res., 1987, 47, 4361–4365.
47 B. Chazotte, Cold Spring Harb Protoc., 2011, 2011, 895–897.
48 S. W. Perry, J. P. Norman, J. Barbieri, E. B. Brown and H. A. Gelbard, BioTechniques, 2011, 50, 98–115.
49 Y. B. Qi, E. J. Garren, X. Shu, R. Y. Tsien and Y. Jin, Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 7499–7504.
50 J. D. Ly, D. R. Grubb and A. Lawen, Apoptosis, 2003, 8, 115–128.